Crizotinib과 한방치료를 병행하여 호전된 ROS1 양성 재발성 폐암 환자 1례 = A Case Report on ROS1-positive Recurrent Non-small-cell Lung Cancer Treated with Crizotinib and Korean Medicine

다국어 초록 (Multilingual Abstract)

Objectives: This study examined the case of a patient with ROS1-positive recurrent non-small-cell lung cancer treated with crizotinib and traditional Korean medicine. Methods: The patient was treated with crizotinib from January 20 2021 to May 22 2021, together with Haedogyangpye-tang and Haengso-tang. The tumor size was measured using computed tomography (CT), and adverse events were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Results: After four months of combined treatment, the sizes of the lymph nodes in the porta hepatis, hepatoduodenal, retrocrural, aortocaval, and para-aortic areas had decreased, and no lymph nodes larger than 1 cm in diameter were observed. The side effects of chemotherapy also improved. Conclusions: This case study suggests that traditional Korean medicine may alleviate the side effects of chemotherapy, improve quality of life, and complement chemotherapy itself.

참고문헌 (Reference)

1 한인선, "항암제로 유발된 백혈구감소증 회복에 미치는 황기의 효과" 대한한방내과학회 27 (27): 579-588, 2006

2 윤탁, "진행성 비소세포폐암의 표적치료 및 맞춤항암치료" 대한내과학회 77 (77): 9-17, 2009

3 김강태, "산두근 추출물이 인체폐암세포의 COX-2 발현 및 PGE2 생성에 미치는 영향" 한의병리학회 21 (21): 907-915, 2007

4 이성옥, "백출 추출물의 암세포증식 저해 효과" 한국생약학회 36 (36): 201-204, 2005

5 정진우, "동충하초 유래 cordycepin의 항암 활성 기전 최근 연구 동향" 한국생명과학회 25 (25): 607-614, 2015

6 이지영, "桔梗이 免疫活性 및 抗癌에 미치는 영향" 대한한방부인과학회 23 (23): 10-19, 2010

7 서운교, "杏蘇湯 및 取淵湯이 호흡기 뮤신 유전자의 발현과 점액분비에 미치는 영향" 대한한의학회 29 (29): 76-87, 2008

8 Kasymjanova G, "The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study" 20 (20): 152-157, 2013

9 Li SG, "The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis" 8 (8): e57604-, 2013

10 김옥, "The Study on Acute and Subacute Toxicity and Sarcoma-180 Anti-cancer Effects of Armeniacae amarum semen Herbal-Acupuncture(Haeng-In)" 대한약침학회 5 (5): 61-79, 2002

11 Dodd MJ, "Symptom clusters and their effect on the functional status of patients with cancer" 28 (28): 465-470, 2001

12 Yang YL, "Separation of Glycoprotein and its Anticancer Immunostimulating Activity from Dried Barks of Slippery Elm [Ulmus parvifolia]" 16 (16): 547-553, 2001

13 Drilon A, "Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials(ALKA-372-001 and STARTRK-1)" 7 (7): 400-409, 2017

14 Sohaib A, "RECIST rules" 12 (12): 345-346, 2012

15 심소현, "Pembrolizumab 면역치료를 시행 중인 비소세포성 폐암환자의 한방치료 증례보고" 대한한방내과학회 40 (40): 709-722, 2019

16 Park JW, "One Case Study of a Non Small Cell Lung Cancer Patient Experiencing Gefitinib Adverse Effects Managed by Traditional Korean Medicine" 17 (17): 9-16, 2012

17 National Comprehensive Cancer Network, "Non-Small Cell Lung Cancer Metastatic"

18 Watanabe H, "New Response Evaluation Criteria in Solid Tumours-Revised RECIST Guideline(version 1.1)" 36 (36): 2495-2501, 2009

19 "Lung Cancer" National Cancer Information Center

20 Chen S, "Integrated Chinese and Western Medicine Treatment of Tumor" People's Medical Publishing House 336-341, 2001

21 박가영, "Inhibitory Effect of Dendrobium moniliforme on NO and IL-1β Production in LPS-stimulated Macrophages" 대한한방안이비인후피부과학회 22 (22): 11-19, 2009

22 Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer" 448 (448): 561-566, 2007

23 Rikova K, "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer" 131 (131): 1190-1203, 2007

24 Sung HA, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries" 71 (71): 209-249, 2021

25 Jung DS, "Factors Affecting Crizotinib-Induced Hepatotoxicity In Non-small Cell Lung Cancer Patients" 35 (35): 154-, 2018

26 Jeon JC, "Effects of Several Medicine Herb Prescriptions on Lung Carcinoma Cells" 21 (21): 621-631, 2000

27 Shaw AT, "Crizotinib in ROS1-rearranged non-small-cell lung cancer" 371 (371): 1963-1971, 2014

28 Collisson E, "Comprehensive molecular profiling of lung adenocarcinoma" 511 (511): 543-550, 2014

29 "Common Terminology Criteria for Adverse Events (CTCAE)" National Cancer Institute

30 Wu X, "Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients: Overview of Systematic Reviews and Network Meta-Analysis" 95 (95): e2410-, 2016

31 Li TM, "Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan" 213 : 92-100, 2018

32 김균하, "Afatinib 표적항암치료를 시행 중인 흉막 전이된 비소세포폐암 환자의 한방치료 증례보고" 대한한방내과학회 41 (41): 1255-1264, 2020

33 Camidge DR, "Activity and safety of Crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase 1study" 13 (13): 1011-1019, 2012

34 Gainor JF, "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer" 19 (19): 4273-4281, 2013